Sh­ionogi's Covid an­tivi­ral lands first ap­proval in Japan's new emer­gency ap­proval path­way

Japan­ese reg­u­la­tors on Tues­day signed off on Sh­iono­gi’s home­grown an­tivi­ral for Covid-19, known as Xo­co­va (en­sitrelvir), mak­ing it the first ap­proval un­der Japan’s emer­gency reg­u­la­to­ry …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER